Single-agent Topotecan in Platinum-resistant Recurrent Ovarian Cancer: a Study in Viet Nam National Cancer Hospital
Year: 2024
Type: article
Abstract: Platinum-based doublet chemotherapy is still supposed as standard regimen in ovarian cancer. However, the rate of relapse or refractory is also very high and vary from 80-85% with stage III-IV ovarian cancer [1]. The prognosis of platinum-resistant ovarian cancer (relapse or refractory within 6 months after initial treatment) has a median survival of 9–12 months and less than 15% respond to subsequent chemotherapy [2]. Thesedays, there are several agents were introduced to control this disease such as Docetaxel, Etoposid, Gemcitabine, Liposomal doxorubicin with overall response rate vary from 12-27% [3] [4] [5]. The objective of this study was to evaluate response and toxicity of 5-day Topotecan chemotherapy in women with primary and secondary platinum-resistant epithelial ovarian cancer.
Source: Tạp chí Y học Việt Nam
Authors: Tuan Anh Pham, Phuong Anh Nguyen
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4404858975